Clinical Trials Logo

Breast Cancer clinical trials

View clinical trials related to Breast Cancer.

Filter by:

NCT ID: NCT00277160 Completed - Breast Cancer Clinical Trials

A Study of Primary Prophylaxis With Neulasta (Pegfilgrastim) Versus Secondary Prophylaxis After Chemotherapy in Elderly Subjects (>/= 65 Years Old) With Cancer

Start date: June 2002
Phase: Phase 4
Study type: Interventional

The purpose of this study is to assess pegfilgrastim starting with the first cycle versus secondary prophylaxis on neutropenic events (including neutropenia +/- fever, dose delays, dose reductions, and hospitalizations) in older patients receiving chemotherapy.

NCT ID: NCT00276536 Completed - Breast Cancer Clinical Trials

Interferon Alfa in Treating Patients With Stage IV Solid Tumors, Lymphoma, or Myeloma

IFNa
Start date: January 2001
Phase: Phase 1
Study type: Interventional

RATIONALE: Interferon alfa may interfere with the growth of cancer cells and slow the growth of cancer. PURPOSE: This phase I trial is studying the side effects and best dose of interferon alfa in treating patients with stage IV solid tumors, lymphoma, or myeloma.

NCT ID: NCT00276211 Completed - Breast Cancer Clinical Trials

Diffusion Weighted MRI for Lymphnodes in the Axilla

Start date: January 2006
Phase: N/A
Study type: Observational

This study is going to compare diffusionweigthed MRI scanning to the result of surgey in patients with metastasis from brestcancer in the axilla

NCT ID: NCT00275041 Completed - Breast Cancer Clinical Trials

Irinotecan and Cetuximab in Treating Patients With Metastatic Breast Cancer

Start date: February 2006
Phase: Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy, such as irinotecan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Giving irinotecan together with cetuximab may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving irinotecan together with cetuximab works in treating patients with metastatic breast cancer.

NCT ID: NCT00274768 Completed - Breast Cancer Clinical Trials

Capecitabine in Treating Patients With Metastatic Breast Cancer

Start date: April 2004
Phase: Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy, such as capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. PURPOSE: This phase II trial is studying how well capecitabine works in treating patients with metastatic breast cancer.

NCT ID: NCT00270907 Completed - Breast Cancer Clinical Trials

CT-2103 in Combination With Gemcitabine in Metastatic Breast Cancer

Start date: December 2005
Phase: Phase 1
Study type: Interventional

The goal of this phase I clinical study is to find the highest safe dose of gemcitabine and CT-2103 that can be given in combination for the treatment of metastatic breast cancer. The safety and effectiveness of this combination will also be studied. This clinical trial will be offered to patients who are being considered for treatment with gemcitabine. Research lab samples and research biopsies will not be requested as part of this study.

NCT ID: NCT00270491 Completed - Breast Cancer Clinical Trials

Capecitabine Associated With Weekly Paclitaxel in Metastatic Breast Cancer.

Start date: December 2005
Phase: Phase 2
Study type: Interventional

Tolerance and efficacy of administration of capecitabine 5 out of 7 days associated with weekly paclitaxel compared to the recommended treatment plan of weekly paclitaxel - capecitabine, in patients with metastatic breast cancer.

NCT ID: NCT00270166 Completed - Breast Cancer Clinical Trials

The Effect of Epoetin Alfa on the Anemia of Patients With Selected Cancers Receiving Chemotherapy

Start date: February 1995
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the safety and effectiveness of epoetin alfa versus placebo in reducing or preventing the need for transfusions in anemic patients with cancer receiving chemotherapy, and to investigate possible quality-of-life benefits associated with the use of epoetin alfa. Epoetin alfa is a genetically engineered protein that stimulates red blood cell production.

NCT ID: NCT00268918 Completed - Breast Cancer Clinical Trials

Docetaxel and PTK787 in Metastatic Breast Cancer Patients and Gynecological Cancer Patients

Start date: September 2005
Phase: Phase 1
Study type: Interventional

The main purpose of this study is to see if the study drug, PTK787, is safe and to find the highest dose that can be given safely without causing serious side effects.

NCT ID: NCT00268502 Completed - Breast Cancer Clinical Trials

Quality of Life in African-American or Caucasian Female Breast Cancer Survivors

Start date: December 2005
Phase: N/A
Study type: Observational

RATIONALE: Studying quality of life in cancer survivors may help determine the long-term effects of breast cancer and may help improve the quality of life for future cancer survivors. PURPOSE: This clinical trial is studying the quality of life in African-American or Caucasian female breast cancer survivors.